 |
|
|
| |
Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone
|
| |
| |
EASL 2024 June 5-8 Milan Italy
Kosh Agarwal1, Man-Fung Yuen2, Stuart Roberts3, Gin-Ho Lo4, Chao-Wei Hsu5, Wan-Long Chuang6, Chi-Yi Chen7, Pei-Yuan Su8, Sam Galhenage9, Sheng-Shun Yang10, Emily P. Thi11, Katie Anderson12, Deana Antoniello13, Elina
Medvedeva13, Timothy Eley13, Tilly Varughese13, Louise Bussey12, Charlotte Davis12, Antonella Vardeu12,
Christine L. Espiritu11, Sharie C. Ganchua11, Christina Iott11, Tom Evans12, Karen D. Sims13
|
| |
|
|
|
|
|
